2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015
December 14, 2017Catalyst Biosciences Announces Appointment of Edward Williams to its Board of DirectorsDecember 09, 2017Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology ConferenceNovember 28, 2017Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership TeamNovember 02, 2017Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate UpdateNovember 01, 2017Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for HematologyOctober 26, 2017Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of DirectorsOctober 24, 2017Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal DiseasesSeptember 26, 2017Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia BSeptember 25, 2017Catalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical TrialSeptember 22, 2017Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceSeptember 11, 2017Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia ProgramSeptember 06, 2017Catalyst Biosciences Announces Positive Factor IX Clinical DataAugust 03, 2017Catalyst Biosciences Reports Second Quarter 2017 Financial Results and Provides Subcutaneous (SQ) Hemophilia Program UpdateJuly 06, 2017Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX ProgramJune 28, 2017Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation in EuropeJune 26, 2017Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing ModelJune 14, 2017Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical TrialJune 08, 2017Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) MeetingMay 31, 2017Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in EuropeMay 11, 2017Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate UpdateApril 12, 2017Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionApril 11, 2017Key Milestone Reached in Catalyst’s Subcutaneous Factor IX ProgramApril 07, 2017Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public OfferingMarch 30, 2017Catalyst Biosciences Announces Emergence from Key Patent Opposition Period Supporting Marzeptacog Alfa (activated), Catalyst’s Lead Clinical ProgramMarch 28, 2017Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX ProgramMarch 08, 2017Catalyst Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateFebruary 16, 2017Catalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of Technical OperationsFebruary 14, 2017Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor ConferenceFebruary 10, 2017Catalyst Biosciences Announces 1-for-15 Reverse Stock SplitFebruary 03, 2017Catalyst Biosciences to Present at 19th Annual BIO CEO & Investor ConferenceFebruary 01, 2017Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factors VIIa and IX at EAHAD Annual CongressJanuary 26, 2017Catalyst Biosciences Announces Multiple Data Presentations at the 2017 Congress of the European Association of Haemophilia and Allied Disorders